Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
IVVD
IVVD
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
IVVD News
Invivyd Aligns with FDA on LIBERTY Phase 3 Trial for VYD2311
Feb 03 2026
seekingalpha
Invivyd Launches LIBERTY Clinical Trial for VYD2311
Feb 03 2026
Newsfilter
Invivyd Initiates Phase 2 Trial for VYD2311 Targeting Long COVID Patients
Jan 20 2026
Newsfilter
Invivyd Reports Q4 2025 Revenue of $17.2M, Up 25% Year-over-Year
Jan 08 2026
Globenewswire
Invivyd Receives FDA Fast Track Designation for VYD2311 Vaccine
Dec 23 2025
Globenewswire
Invivyd Initiates Phase 3 DECLARATION Trial for VYD2311 with 1770 Participants
Dec 23 2025
Globenewswire
BTIG Initiates Buy Rating on Invivyd Inc with $10 Price Target
Dec 22 2025
Benzinga
Staar Surgical and Gold Royalty Experience Activist Involvement
Nov 26 2025
Barron's
Coinbase Analyst Changes Stance; Check Out Tuesday's Top 5 Downgrades
Nov 25 2025
Benzinga
Invivyd Unveils VBY329 Monoclonal Antibody for RSV Prevention, Targeting $4 Billion Market
Nov 24 2025
Newsfilter
Major Stocks Including Helmerich and Payne, Invivyd, and Home Depot Decline in Tuesday's Pre-Market Trading
Nov 18 2025
Benzinga
Gorilla Technology Shares Rise Approximately 14%; Check Out 20 Stocks Making Moves in Premarket Trading
Nov 18 2025
Benzinga
Invivyd Sets Price for $125 Million Public Offering of Common Stock and Pre-Funded Warrants
Nov 18 2025
Newsfilter
Invivyd Initiates Public Stock Offering
Nov 17 2025
Yahoo Finance
Major Stocks on the Rise Monday: Jazz Pharmaceuticals, Sigma Lithium, Zymeworks, and More
Nov 17 2025
Benzinga
Friday's Top Performers: Oil & Gas Refining & Marketing and Biotechnology Stocks
Nov 14 2025
NASDAQ.COM
Show More News
